Sponsored by:

Nuclear Medicine: Page 233

PET/CT helps target radiation therapy of NSCLC tumors
By Becky McCall
LONDON - PET/CT prior to radiotherapy can help oncologists target a more powerful dose of radiation to non-small cell lung cancer (NSCLC), whilst keeping dose low in other areas of the organ, according to research presented at this week's European Society for Therapeutic Radiology and Oncology meeting.
May 11, 2011
2011 05 11 14 00 56 747 Estro Clinical 394
U. of Iowa professor files lawsuit
By AuntMinnie.com staff writers
A nuclear medicine physician involved in a dispute with his employer, the University of Iowa, has filed a lawsuit against the university, claiming that he was the victim of harassment, retaliation, and racial bias.
May 10, 2011
Molecular Targeting licenses dyes from MGH
By AuntMinnie.com staff writers
Medical imaging products developer Molecular Targeting Technologies has received an exclusive license from Massachusetts General Hospital (MGH) and Harvard Medical School for novel fluorescence dyes.
May 10, 2011
Telemis debuts PC-based PET/CT viewer
By AuntMinnie.com staff writers
PACS vendor Telemis has introduced version 4.2 of its TM-ReceptionHE image management software, which features a PC-based PET/CT viewer.
May 9, 2011
Hitachi lands Mayo Clinic proton therapy order
By AuntMinnie.com staff writers
Hitachi will provide the Mayo Clinic with two proton beam therapy systems, which will be installed at Mayo facilities in Rochester, MN, and Phoenix.
May 9, 2011
Neoprobe revenue up, but loss widens in Q1
By AuntMinnie.com staff writers
Grant revenue related to its Lymphoseek radiopharmaceutical development efforts helped Neoprobe to an approximate 6% increase in first-quarter revenue. But accounting adjustments contributed to a wider net loss.
May 9, 2011
IBA, Philips join forces in proton therapy
By AuntMinnie.com staff writers
Radiopharmaceutical developer Ion Beam Applications (IBA) and Royal Philips Electronics have inked a deal to create proton therapy centers.
May 8, 2011
Molecular Insight to exit Chapter 11
By AuntMinnie.com staff writers
Radiopharmaceutical developer Molecular Insight Pharmaceuticals said it is scheduled to emerge from Chapter 11 bankruptcy protection as a fully restructured company by late May.
May 8, 2011
Delayed I-131 therapy can be costly for thyroid patients
By Wayne Forrest
Delaying initial radioactive iodine-131 (I-131) therapy more than 180 days after total thyroidectomy may result in poor survival for thyroid carcinoma patients, according to a study published in the May issue of the Journal of Nuclear Medicine.
May 8, 2011
Naviscan touts ARRS PEM study
By AuntMinnie.com staff writers
PET developer Naviscan is touting a study that shows that positron emission mammography (PEM) is useful for performing local staging in women with newly diagnosed breast cancer.
May 2, 2011
Eckert & Ziegler grows Q1 revenues
By AuntMinnie.com staff writers
Earnings from its isotope products segment powered Eckert & Ziegler, parent company of radiotherapy and radioisotope developer Eckert & Ziegler Isotope Products, to a prosperous first quarter.
May 2, 2011
SNM proposes name change
By AuntMinnie.com staff writers
The SNM Board of Directors and House of Delegates, in conjunction with the leadership of the society's Technologist Section, have proposed changing the organization's name to the Society of Nuclear Medicine and Molecular Imaging.
May 2, 2011
Previous Page
Page 233 of 440
Next Page